I have training in pharmacology and cancer research with an interest in cancer drug discovery and development. My research for the past 25 years has studied the molecular basis for the antineoplastic activity of nonsteroidal anti-inflammatory drugs (NSAIDs). My research in the pharmaceutical industry supported the preclinical development of the non-COX inhibitory sulfone metabolite of sulindac, exisulind, to treat precancerous adenomas in patients with familial adenomatous polyposis (FAP) that was advanced to Phase 3 clinical trials and showed promising efficacy but did not receive FDA approval due to hepatotoxicity.


  • RAS-related publications
  • PDE10-related publications
  • Preclinical drug development
  • Drug Discovery
Past Affiliations

Professor, Department of Pharmacology, Frederick P. Whiddon College of Medicine, University of South Alabama (past)

Professor, Mitchell Cancer Institute, University of South Alabama (past)

PhD, University of Alabama at Birmingham, Pharmacology, 1985
BS, Dominican University, Biology and Psychology, 1981